Text Size
Trial record 19 of 72 for:    Open Studies | "Dermatitis, Atopic"
Previous Study | Return to List | Next Study

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

This study is currently recruiting participants.
Verified December 2012 by Asubio Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Asubio Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01756898
First received: November 9, 2012
Last updated: December 27, 2012
Last verified: December 2012
History of Changes
  Purpose

The purpose of this research study is to gather scientific information about the effectiveness of the study drug, ASB17061 capsules, when compared to placebo in adult subjects with atopic dermatitis.


Condition Intervention Phase
Atopic Dermatitis
 Drug: ASB17061
Drug: Placebo
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Resource links provided by NLM:

MedlinePlus related topics: Eczema
U.S. FDA Resources

Further study details as provided by Asubio Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Investigator's Global Assessment (IGA) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Eczema Area and Severity Index Score (EASI) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • The Percentage of Body Surface Area (BSA) Involved [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Pruritus Score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Insomnia Score [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Number of Patients with Abnormal Findings in Electrocardiograms, Serum Biomarkers, Clinical Laboratory Test, and Vital Signs [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Population Pharmacokinetics: AUC and Cavg [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Number of Patients with Adverse Events [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 360
Study Start Date: December 2012
Estimated Study Completion Date: November 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose ASB17061
Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
 Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Experimental: Middle dose ASB17061
Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
 Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Experimental: High dose ASB17061
Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
 Drug: ASB17061
Oral administration of ASB17061 taken once daily for 28 consecutive days.
Placebo Comparator: Placebo
Oral administration of placebo taken once daily for 28 consecutive days.
 Drug: Placebo
Oral administration of placebo taken once daily for 28 consecutive days.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult subjects ages 18 to 65 years
  • A diagnosis of atopic dermatitis (AD)
  • An IGA score of 2 or higher and AD affecting at least 5% of total Body Surface Area (BSA)
  • Other than active AD, in good health with no medical condition that may jeopardize the safety of the subject or impact the validity of the study results
  • Subjects must be practicing acceptable birth control methods

Exclusion Criteria:

  • Taking systemic immunosuppressive therapy within 3 months prior to screening or systemic (cortico) steroid therapy within 4 weeks prior to screening
  • Use of phototherapy or tanning beds within 6 weeks of screening
  • Presence of a clinically significant disorder involving gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition, which will jeopardize the safety of the subject or impact the validity of the study results
  • Female subjects who are pregnant or breastfeeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01756898

Contacts
Contact: Sindee Grossman 201-368-5035 sgrossman@asubio.com

  Show 27 Study Locations
Sponsors and Collaborators
Asubio Pharmaceuticals, Inc.
Investigators
Study Director: Ger Rikken, MD Asubio Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Asubio Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01756898     History of Changes
Other Study ID Numbers: ASBI 704
Study First Received: November 9, 2012
Last Updated: December 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Asubio Pharmaceuticals, Inc.:
Atopic Dermatitis
eczema

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
 Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 16, 2013